Increased Blood Pressure Variability and the Risk of Probable Dementia or Mild Cognitive Impairment: A Post Hoc Analysis of the SPRINT MIND Trial.

Background Increased systolic blood pressure variability (BPV) is associated with stroke, cardiovascular disease, and dementia and mild cognitive impairment. However, prior studies assessing the relationship between BPV and dementia or mild cognitive impairment had infrequent measurement of blood pressure or suboptimal blood pressure control. Methods and Results We performed a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial) MIND (Memory and Cognition in Decreased Hypertension) trial. The primary outcome was probable dementia during follow-up. We defined our exposure period, during which blood pressures were collected, as the first 600 days of the trial, and outcomes were ascertained during the subsequent follow-up. BPV was measured as tertiles of systolic blood pressure standard deviation. We fit Cox proportional hazards models to our outcome. We included 8379 patients. The mean follow-up was 3.2±1.4 years, during which 316 (3.8%) patients developed dementia. The mean number of blood pressure measurements was 7.8, and in the tertiles of BPV, the SD was 6.3±1.6, 10.3±1.1, and 16.3±3.6 mm Hg, respectively. The rate of dementia was 2.4%, 3.6%, and 5.4% by ascending tertile, respectively (P<0.001). In the Cox models, compared with the lowest tertile of BPV, the highest tertile of BPV increased the risk of dementia in both unadjusted (hazard ratio [HR], 2.36; 95% CI, 1.77-3.15) and adjusted (HR, 1.69; 95% CI, 1.25-2.28) models. Conclusions In a post hoc analysis of the SPRINT MIND trial, we found that higher BPV was associated with the development of probable dementia despite excellent blood pressure control. Additional research is needed to understand how to reduce BPV and if its reduction lowers the risk of cognitive impairment and dementia.

Increased systolic blood pressure variability (BPV) has been linked to the development of stroke, cardiovascular disease, and dementia and mild cognitive impairment (MCI), independent of mean blood pressure. , In addition, research has demonstrated the importance of blood pressure control for the prevention of dementia and MCI. However, previous studies evaluating the relationship between BPV and dementia or MCI relied on longitudinal cohorts, with infrequent measurement of blood pressure or suboptimal blood pressure control. We hypothesized that in a cohort with frequent visit‐to‐visit blood measurements and excellent blood pressure control, BPV would retain its harmful effects on cognition.

Methods

We performed a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial) MIND (Memory and Cognition in Decreased Hypertension) trial, using a publicly available deidentified data set supplied by the National Heart, Lung, and Blood Institute. Institutional review board approval or participant consent was not required for this post hoc analysis of deidentified data per University of Utah institutional review board policy. Our primary outcome was incident probable dementia, and secondary outcomes were MCI and the composite of dementia/MCI. The rigorous adjudication of probable dementia and MCI in the SPRINT MIND trial has previously been described and relied on both screening and adjudication at follow‐up visits and planned cognitive testing at years 2 and 4, and study closeout when it was >1 year after the year‐4 evaluation. We defined our exposure period, during which blood pressures were collected at study visits, as the first 600 days of the SPRINT trial, and outcomes were recorded during the subsequent SPRINT MIND follow‐up period.

The exposure of visit‐to‐visit BPV was measured as tertiles of systolic blood pressure SD, and to improve accuracy of BPV measurement, we excluded patients with <4 blood pressure measurements. In the SPRINT trial, trained study personnel recorded seated blood pressures according to a protocol at scheduled study visits. The blood pressure used in the present study is a single value per visit that represents the average of 3 seated blood pressures at each study visit. To standardize the time between blood pressure measurements, we excluded as‐needed study visit blood pressures, and to limit the confounding of trial interventions, we also excluded the baseline visit blood pressure. We included blood pressures from up to 9 scheduled visits at 1, 2, 3, 6, 9, 12, 15, 18, and 21 months from enrollment. We calculated the SD using the formula:

We fit Cox proportional hazards models to our outcomes and a priori adjusted for patient age, sex, race/ethnicity, history of cardiovascular disease, hypertension, education, level of physical activity, current smoking status, SPRINT randomization arm, number of blood pressure measurements, and mean systolic blood pressure during the exposure. We verified the proportional hazards assumption of our final model (global test, P=0.498). We also included the interaction of randomization arm×BPV in our model and then stratified by randomization arm to explore the effect of BPV in patients with standard versus intensive blood pressure control. We subsequently tested the interactions between BPV and the other covariates in our adjusted model. As a sensitivity analysis, we confirmed our results using coefficient of variation and residual SD to generate tertiles of BPV, instead of SD. All analyses were performed in Stata 16.1 (StataCorp, College Station, TX).

Results

Of the 8563 patients who completed at least 1 cognitive assessment in the SPRINT MIND trial, we included 8379 and excluded 110 for insufficient blood pressure data, 24 for having the outcome or being right‐censored during the exposure period, and 32 for having missing demographic data or covariates in our adjusted model. Baseline demographics are shown in Table 1. During the 600‐day exposure period, the mean number of systolic blood pressure measurements was 7.8±0.6, and mean systolic blood pressure was 128.5 mm Hg. In the tertiles of BPV, the SD was 6.3±1.6, 10.3±1.1, and 16.3±3.6 mm Hg, respectively. The mean follow‐up was 3.2±1.4 years, during which 316 (3.8%) patients developed dementia. In tertiles of increasing BPV, the rate of dementia was 2.4%, 3.6%, and 5.4%, respectively (P<0.001). Similar increases were seen for the secondary outcomes (Table 1).

Table 1

Baseline Demographics in the Full Cohort and Tertiles of BPV

Variable	Full cohort, n=8379	Lowest tertile of BPV, n=2796	Middle tertile of BPV, n=2791	Highest tertile of BPV, n=2792	P value*
Age, y	67.9±9.3	66.7±8.9	67.8±9.1	69.1±9.5	<0.001
Age ≥75 y	2049 (24.5%)	564 (20.2%)	644 (23.1%)	841 (30.1%)	<0.001
Male sex	5438 (64.9%)	1968 (71.0%)	1849 (66.3%)	1603 (57.4%)	<0.001
Race/ethnicity
White	4913 (58.6%)	1589 (56.8%)	1730 (62.0%)	1594 (57.1%)	<0.001
Black	2458 (29.3%)	807 (28.9%)	753 (27.0%)	898 (32.2%)
Hispanic	866 (10.4%)	349 (12.5%)	265 (9.5%)	252 (9.0%)
Other†	142 (1.7%)	51 (1.8%)	43 (1.5%)	48 (1.7%)
History of diabetes	137 (1.6%)	34 (1.2%)	49 (1.8%)	54 (1.9%)	0.088
History of hypertension	7779 (92.8%)	2553 (91.3%)	2588 (92.7%)	2638 (94.5%)	<0.001
History of peripheral vascular disease, n=8371	448 (5.4%)	121 (4.3%)	137 (4.9%)	190 (6.8%)	<0.001
History of atrial fibrillation, n=8366	657 (7.9%)	198 (7.1%)	208 (7.5%)	251 (9.0%)	0.017
History of cardiovascular disease	1663 (19.9%)	494 (17.7%)	518 (18.6%)	651 (23.3%)	<0.001
History of stroke, n=8377	44 (0.5%)	14 (0.5%)	11 (0.4%)	19 (0.7%)	0.325
Smoking
Never	3713 (44.3%)	1276 (45.6%)	1237 (44.3%)	1200 (43.0%)	<0.001
Past	3601 (43.0%)	1219 (43.6%)	1201 (43.0%)	1181 (42.3%)
Current	1065 (12.7%)	301 (10.8%)	353 (12.7%)	411 (14.7%)
Alcoholism	324 (3.9%)	95 (3.4%)	112 (4.0%)	117 (4.2%)	0.270
Vigorous physical activity
≤1/wk	4486 (53.6%)	1406 (50.3%)	1486 (53.2%)	1594 (57.1%)	<0.001
1–4/wk	2767 (33.0%)	993 (35.5%)	902 (32.3%)	872 (31.2%)
≥5/wk	1126 (13.4%)	397 (14.2%)	403 (14.5%)	326 (11.7%)
Aspirin use	4313 (51.5%)	1422 (50.9%)	1428 (51.2%)	1463 (52.4%)	0.481
Retired	5036 (60.1%)	1558 (55.7%)	1689 (60.5%)	1789 (64.1%)	<0.001
Education
Less than college/other	5053 (60.3%)	1611 (57.6%)	1655 (59.3%)	1787 (64.0%)	<0.001
College	1227 (14.6%)	437 (15.6%)	412 (14.8%)	378 (13.5%)
Grad school	2099 (25.1%)	748 (26.8%)	724 (25.9%)	627 (22.5%)
Randomized to intensive blood pressure arm	4214 (50%)	1498 (53.3%)	1412 (50.3%)	1304 (46.4%)	<0.001
Mean no. of antihypertensive medications during follow‐up	2.7±1.2	2.5±1.1	2.7±1.2	3.0±1.2	<0.001
No. of blood pressure measurements	7.8±0.7	7.8±0.7	7.8±0.7	7.7±0.7	0.002
Mean systolic blood pressure during the exposure	128.5±9.8	126.2±9.7	128.1±9.3	131.2±9.8	<0.001
Percentage of study visits with hypotension, SBP <90 or DBP <50 mm Hg	2.1±8.5	1.2±6.9	1.7±7.7	3.4±10.3	<0.001
Systolic blood pressure at the beginning of the exposure	128.4±14.6	126.1±11.4	127.9±13.1	131.1±18.1	<0.001
Systolic blood pressure at the end of the exposure	127.6±14.9	125.9±11.6	127.2±13.4	129.6±18.5	<0.001
Standard deviation of systolic blood pressure	10.9±4.7	6.3±1.6	10.3±1.1	16.3±3.6	<0.001

P value is for the comparison between the tertiles of BPV, tested with the χ2 test for binary variables and ANOVA for interval variables. Binary variables are presented as n (%) and interval variables as mean±SD. BPV indicates blood pressure variability; DBP, diastolic blood pressure; and SBP, systolic blood pressure.

SPRINT.

In the Cox models, the highest tertile of BPV, compared with the lowest, increased the risk of dementia in both unadjusted (hazard ratio [HR], 2.36; 95% CI, 1.77–3.15) and adjusted (adjusted HR, 1.69; 95% CI, 1.25–2.28) models (Table 2). For the secondary outcomes, we found that the highest tertile of BPV was associated with both MCI (adjusted HR, 1.40; 95% CI, 1.14–1.71), and the composite of dementia/MCI (adjusted HR, 1.43; 95% CI, 1.20–1.71) (Table 2). The interaction term between randomization arm and BPV was not significant (P=0.557), indicating that the effect of BPV was present in both the standard and intensive blood pressure control arms. The Kaplan‐Meier curves for the tertiles of BPV after stratification by randomization arm are shown in the Figure and demonstrate a consistent relationship between higher BPV and the risk of dementia in both randomization arms.

Table 2

Event Rate of the Outcomes by Tertiles of Systolic Standard Deviation and Cox Proportional Hazards Models Fit to the Outcomes

Outcome	Tertile of systolic standard deviation (range in mm Hg)	Event rate, n, %	Unadjusted hazard ratio (95% CI)	P value	Adjusted hazard ratio* (95% CI)	P value
Probable dementia	Lowest (0.5–8.5)	67/2796, 2.4%	Ref	…	Ref	…
	Middle (8.5–12.3)	99/2791, 3.6%	1.51 (1.11–2.06)	0.009	1.39 (1.02–1.91)	0.037
	Highest (12.3–41.1)	150/2792, 5.4%	2.36 (1.77–3.15)	<0.001	1.69 (1.25–2.28)	0.001
Mild cognitive Impairment	Lowest (0.5–8.5)	169/2796, 6.0%	Ref	…	Ref	…
	Middle (8.5–12.3)	195/2791, 7.0%	1.18 (0.96–1.45)	0.119	1.13 (0.92–1.40)	0.237
	Highest (12.3–41.1)	264/2792, 9.5%	1.64 (1.36–2.00)	<0.001	1.40 (1.14–1.71)	0.002
Composite of probable dementia and mild cognitive impairment	Lowest (0.5–8.5)	218/2796, 7.8%	Ref	…	Ref	…
	Middle (8.5–12.3)	264/2791, 9.5%	1.24 (1.04–1.48)	0.020	1.17 (0.97–1.40)	0.094
	Highest (12.3–41.1)	370/2792, 13.3%	1.94 (1.51–2.11)	<0.001	1.43 (1.20–1.71)	<0.001

Adjusted for patient age, sex, race/ethnicity, history of cerebrovascular disease, hypertension, education, level of physical activity, smoking status, percentage of study visits during the exposure with hypotension (SBP <90 or DBP <50 mm Hg), mean SBP during the exposure, and randomization arm. DBP indicates diastolic blood pressure; Ref, reference; and SBP, systolic blood pressure.

Figure 1

Kaplan‐Meier curves showing failure rates for probable dementia in the first 1500 days of follow‐up after stratification by the standard vs intensive blood pressure reduction arm in SPRINT.

BP indicates blood pressure; HR, hazard ratio; MCI, mild cognitive impairment; and SPRINT, Systolic Blood Pressure Intervention Trial.

We tested the interactions between BPV and the other covariates in our adjusted model and found that none had a significant interaction (all P>0.1). In the sensitivity analysis, where we used coefficient of variation and residual standard deviation to make tertiles of BPV, we found consistent results. For example, in the adjusted model fit to our primary outcome, the HR for dementia in the top tertile of coefficient of variation was 1.53 (95% CI, 1.15–2.05), whereas in the top tertile of residual standard deviation it was 1.81 (95% CI, 1.33–2.46).

Discussion

In a post hoc analysis of the SPRINT MIND trial, we found that visit‐to‐visit BPV was associated with the development of probable dementia, MCI, and the composite of both. This association was present in both the standard and intensive target blood pressure randomization arms, indicating residual risk in the intensive arm, some of which may be attributable to BPV. The implication of these findings is that BPV has an impact on cognition independent of mean blood pressure. Prior longitudinal studies have found similar findings, but either relied on blood pressure readings at study visits separated by years, , , , daily readings for less than a month, or dementia adjudication that was not as robust. In addition, the existing data are largely from community‐dwelling cohorts with higher mean blood pressure than the SPRINT MIND cohort. We show that despite the excellent blood pressure control in the SPRINT MIND trial, BPV remains a risk factor for developing cognitive impairment, which is a key outcome for older adults and warrants additional preventative research and routine screening in primary care.

There are several potential explanations for the association between increased BPV and dementia or MCI. Although increased BPV has been associated with a higher risk of stroke, which is associated with dementia, we did not find a difference in the rate of stroke in the tertiles of BPV. Secondary to the stiffer arteries that can cause increased BPV, BPV has been linked to intermittent cerebral hypoperfusion, which can predispose to vascular dementia. A study also showed an association between increased BPV and neurofibrillary tangle pathology on autopsy, which is the hallmark of Alzheimer disease, as opposed to vascular dementia. Hypotension has been identified as a potential risk factor for the development of dementia. Although we found that hypotension at study visits was more common in patients in higher tertiles of BPV, we adjusted for hypotension in our multivariate models, and the association between increased BPV and dementia remained significant.

Ultimately, the exact mechanism by which increased BPV may cause dementia remains uncertain, and increased BPV may be an epiphenomenon of another unidentified causal mechanism. Although post hoc analyses can identify a potential risk factor, there is always unmeasured confounding. A randomized clinical trial that attempts to lower the variability and mean of blood pressure, and with the end point of dementia or MCI, will be necessary to determine if BPV is a viable treatment target. Because both short‐term and longer‐term visit‐to‐visit increased BPV have both been associated with dementia and cardiovascular events, , to identify patients with increased BPV for such a trial, the inclusion criteria could have a qualifying period with 12 or 24 hours of ambulatory blood pressure monitoring. Prior research has shown that calcium channel blockers can reduce BPV, but the goal of reducing both systolic blood pressure mean and variability will require sophisticated medication titration. Before a clinical trial can address the question of the therapeutic effects of lowering BPV, additional research is needed to determine how BPV will be reduced and if that reduction is safe.

Our study has several limitations, including that it is a post hoc analysis of a trial that was not designed to answer the proposed hypothesis. There are not identical exposures between patients, because the frequency of blood pressure measurement was dependent on the randomization arm, which may have introduced bias, although the mean number of measurements in the standard versus intensive arm did not differ significantly (7.8 versus 7.8 measurements, respectively; P=0.53), and the difference in the tertiles of BPV was not meaningfully different. We also were not able to examine neuroimaging mediators of the observed association, such as chronic microvascular disease or brain atrophy, because repeat brain magnetic resonance imaging was only available in a subset of patients, and the final study magnetic resonance imaging was at 48 months. The strengths of our study are that the outcome of dementia was rigorously adjudicated in the SPRINT MIND trial, patients had excellent blood pressure control, and we had an average of 7.8 blood pressure readings available for determining BPV.

Conclusions

In the SPRINT MIND study, blood pressure variability during the first 600 days was associated with subsequent development of probable dementia or MCI, despite excellent blood pressure control. The practical implication of this finding is that additional research is needed to understand how to reduce blood pressure variability and if its reduction lowers the risk of cognitive impairment and dementia.

Sources of Funding

Dr de Havenon reports National Institutes of Health/National Institute of Neurological Disorders and Stroke funding (K23NS105924).

Disclosures

Dr de Havenon has received investigator‐initiated clinical research funding from Regeneron and AMAG pharmaceuticals. The remaining authors have no disclosures to report.